The Antiangiogenic Effects of a Vascular Endothelial Growth Factor Decoy Receptor Can Be Monitored in Vivo Using Contrast-Enhanced Ultrasound Imaging
The development of antiangiogenic therapies has stimulated interest in noninvasive imaging methods to monitor response. We investigated whether the effects of a vascular endothelial growth factor decoy receptor (VEGF Trap, Regeneron Pharmaceuticals, Tarrytown, NY) could be monitored in vivo using co...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2014-03-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2013.00073 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841564083447398400 |
|---|---|
| author | Flemming Forsberg Raymond J. Ro Andrew Marshall Ji-Bin Liu See-Ying Chiou Daniel A. Merton Priscilla Machado Adam P. Dicker Levon N. Nazarian |
| author_facet | Flemming Forsberg Raymond J. Ro Andrew Marshall Ji-Bin Liu See-Ying Chiou Daniel A. Merton Priscilla Machado Adam P. Dicker Levon N. Nazarian |
| author_sort | Flemming Forsberg |
| collection | DOAJ |
| description | The development of antiangiogenic therapies has stimulated interest in noninvasive imaging methods to monitor response. We investigated whether the effects of a vascular endothelial growth factor decoy receptor (VEGF Trap, Regeneron Pharmaceuticals, Tarrytown, NY) could be monitored in vivo using contrast-enhanced ultrasonography (CEUS). Twenty nude mice (in two groups) were implanted with a human melanoma cell line (DB-1). The active group received VEGF Trap (4 × 25 mg/kg over 2 weeks), whereas the control group received an inactive protein. An ultrasound contrast agent was injected followed by power Doppler imaging (PDI) and pulse inversion harmonic imaging (PIHI; regular and intermittent). Specimens were sectioned in the same planes as the images and stained for endothelial cells (CD31), cyclooxygenase-2 (COX-2), VEGF, and hypoxia (Glut1). Measures of tumor vascularity obtained with the different imaging modes were compared to immunohistochemical markers of angiogenesis. Mean tumor volume was smaller in the active group than in the control group (656 ± 225 vs 1,160 ± 605 mm 3 ). Overall, PDI and VEGF correlated ( r = .34; p = .037). Vascularity decreased from control to treated mice with intermittent PIHI, as did the expression of CD31 and COX-2 ( p # .02), whereas VEGF increased ( p = .05). CEUS appears to allow in vivo monitoring of the antiangiogenic effects of VEGF Trap in the DB-1 human melanoma xenograft model. |
| format | Article |
| id | doaj-art-2ee5ff44047040b8a76ac08f99d1ede2 |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2014-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-2ee5ff44047040b8a76ac08f99d1ede22025-01-02T23:12:07ZengSAGE PublishingMolecular Imaging1536-01212014-03-011310.2310/7290.2013.0007310.2310_7290.2013.00073The Antiangiogenic Effects of a Vascular Endothelial Growth Factor Decoy Receptor Can Be Monitored in Vivo Using Contrast-Enhanced Ultrasound ImagingFlemming ForsbergRaymond J. RoAndrew MarshallJi-Bin LiuSee-Ying ChiouDaniel A. MertonPriscilla MachadoAdam P. DickerLevon N. NazarianThe development of antiangiogenic therapies has stimulated interest in noninvasive imaging methods to monitor response. We investigated whether the effects of a vascular endothelial growth factor decoy receptor (VEGF Trap, Regeneron Pharmaceuticals, Tarrytown, NY) could be monitored in vivo using contrast-enhanced ultrasonography (CEUS). Twenty nude mice (in two groups) were implanted with a human melanoma cell line (DB-1). The active group received VEGF Trap (4 × 25 mg/kg over 2 weeks), whereas the control group received an inactive protein. An ultrasound contrast agent was injected followed by power Doppler imaging (PDI) and pulse inversion harmonic imaging (PIHI; regular and intermittent). Specimens were sectioned in the same planes as the images and stained for endothelial cells (CD31), cyclooxygenase-2 (COX-2), VEGF, and hypoxia (Glut1). Measures of tumor vascularity obtained with the different imaging modes were compared to immunohistochemical markers of angiogenesis. Mean tumor volume was smaller in the active group than in the control group (656 ± 225 vs 1,160 ± 605 mm 3 ). Overall, PDI and VEGF correlated ( r = .34; p = .037). Vascularity decreased from control to treated mice with intermittent PIHI, as did the expression of CD31 and COX-2 ( p # .02), whereas VEGF increased ( p = .05). CEUS appears to allow in vivo monitoring of the antiangiogenic effects of VEGF Trap in the DB-1 human melanoma xenograft model.https://doi.org/10.2310/7290.2013.00073 |
| spellingShingle | Flemming Forsberg Raymond J. Ro Andrew Marshall Ji-Bin Liu See-Ying Chiou Daniel A. Merton Priscilla Machado Adam P. Dicker Levon N. Nazarian The Antiangiogenic Effects of a Vascular Endothelial Growth Factor Decoy Receptor Can Be Monitored in Vivo Using Contrast-Enhanced Ultrasound Imaging Molecular Imaging |
| title | The Antiangiogenic Effects of a Vascular Endothelial Growth Factor Decoy Receptor Can Be Monitored in Vivo Using Contrast-Enhanced Ultrasound Imaging |
| title_full | The Antiangiogenic Effects of a Vascular Endothelial Growth Factor Decoy Receptor Can Be Monitored in Vivo Using Contrast-Enhanced Ultrasound Imaging |
| title_fullStr | The Antiangiogenic Effects of a Vascular Endothelial Growth Factor Decoy Receptor Can Be Monitored in Vivo Using Contrast-Enhanced Ultrasound Imaging |
| title_full_unstemmed | The Antiangiogenic Effects of a Vascular Endothelial Growth Factor Decoy Receptor Can Be Monitored in Vivo Using Contrast-Enhanced Ultrasound Imaging |
| title_short | The Antiangiogenic Effects of a Vascular Endothelial Growth Factor Decoy Receptor Can Be Monitored in Vivo Using Contrast-Enhanced Ultrasound Imaging |
| title_sort | antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast enhanced ultrasound imaging |
| url | https://doi.org/10.2310/7290.2013.00073 |
| work_keys_str_mv | AT flemmingforsberg theantiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT raymondjro theantiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT andrewmarshall theantiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT jibinliu theantiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT seeyingchiou theantiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT danielamerton theantiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT priscillamachado theantiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT adampdicker theantiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT levonnnazarian theantiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT flemmingforsberg antiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT raymondjro antiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT andrewmarshall antiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT jibinliu antiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT seeyingchiou antiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT danielamerton antiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT priscillamachado antiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT adampdicker antiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging AT levonnnazarian antiangiogeniceffectsofavascularendothelialgrowthfactordecoyreceptorcanbemonitoredinvivousingcontrastenhancedultrasoundimaging |